# Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

> **NCT04001803** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 115 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** CAB LA+RPV LA

## Key facts

- **NCT ID:** NCT04001803
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-08
- **Primary completion:** 2020-10-05
- **Final completion:** 2022-03-18
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04001803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04001803, "Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT04001803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*